Skip to main content
Erschienen in: International Journal of Clinical Pharmacy 2/2019

27.04.2019 | Research Article

Implementation of a pharmaceutical care program for patients with hepatitis C treated with new direct-action antivirals

verfasst von: María Ángeles Campos Fernández de Sevilla, Marta Gallego Úbeda, Miriam Heredia Benito, Emilio García-Cabrera, Beatriz Monje García, María Tovar Pozo, Laura Delgado Téllez de Cepeda, Irene Iglesias-Peinado

Erschienen in: International Journal of Clinical Pharmacy | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Background A pharmaceutical care program is necessary to improve the management of direct-acting antivirals in hepatitis C. Objective Describe health outcomes obtained with the implementation of a pharmaceutical care program in Hepatitis C patients treated with direct-acting antivirals. Setting This study was performed in a pharmacy department of a university hospital. Methods Retrospective study between 1st-April 2015 and 28st-February 2016. Hospital pharmacists implemented interventional measures for validation of antivirals prescriptions, detection of drug-interaction, adverse drug events, education and patient´s adherence to antiviral regimen. Main outcome measure Health and quality outcomes of the implementation of the pharmaceutical care program. Results A total 128 patients were enrolled. The overall sustained virologic response at week 12 post-treatment rate was 96.1% (95% CI 92.7–99.5). Adverse drug events occurred in 90.6% of the patients, and the majority were grade 1–2. Pharmacists made 334 pharmaceutical interventions. 35.5% of these interventions were aimed to resolve negative results of drugs. 80.9% of the negative results of drugs improved or were eliminated with the application of the measures proposed by the pharmacists (p ≤ 0.001). Pharmacists carried out 175 preventive interventions to avoid negative results of drugs. 97.3% of these interventions were accepted and managed to prevent the appearance of negative results of drugs (p = 0.453). Conclusion The implementation of a pharmaceutical care program in patients with hepatitis C treated with direct-acting antivirals has improved the safety in the use of these drugs.
Literatur
1.
Zurück zum Zitat Terrault N, Monto A, Stinchon MR, Rusie E, Moreo K. New therapies, evidence, and guidance in hepatitis c management: expert practices and insights from an educational symposium at the AMCP 27th annual meeting expo. J Manag Care Spec Pharm. 2015;21(9):S1–14.PubMed Terrault N, Monto A, Stinchon MR, Rusie E, Moreo K. New therapies, evidence, and guidance in hepatitis c management: expert practices and insights from an educational symposium at the AMCP 27th annual meeting expo. J Manag Care Spec Pharm. 2015;21(9):S1–14.PubMed
4.
Zurück zum Zitat Chhatwal J, Chen Q, Aggarwal R. Estimation of hepatitis c disease burden and budget impact of treatment using health economic modeling. Infect Dis Clin North Am. 2018;32(2):461–80.CrossRefPubMed Chhatwal J, Chen Q, Aggarwal R. Estimation of hepatitis c disease burden and budget impact of treatment using health economic modeling. Infect Dis Clin North Am. 2018;32(2):461–80.CrossRefPubMed
5.
Zurück zum Zitat Spooner LM. The critical need for pharmacist involvement in the management of patients with hepatitis C. J Manag Care Pharm. 2009;15(2):151–3.PubMed Spooner LM. The critical need for pharmacist involvement in the management of patients with hepatitis C. J Manag Care Pharm. 2009;15(2):151–3.PubMed
6.
Zurück zum Zitat Mohammad RA, Bulloch MN, Chan J, Deming P, Love B, Smith L, et al. Provision of clinical pharmacist services for individuals with chronic hepatitis C viral infection: joint opinion of the GI/liver/nutrition and infectious diseases practice and research networks of the American College of Clinical Pharmacy. Pharmacotherapy. 2014;34(12):1341–54.CrossRefPubMed Mohammad RA, Bulloch MN, Chan J, Deming P, Love B, Smith L, et al. Provision of clinical pharmacist services for individuals with chronic hepatitis C viral infection: joint opinion of the GI/liver/nutrition and infectious diseases practice and research networks of the American College of Clinical Pharmacy. Pharmacotherapy. 2014;34(12):1341–54.CrossRefPubMed
9.
Zurück zum Zitat Hayashi N, Seto C, Kato M, Komada Y, Goto S. Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1-infected patients in Japan: the DRAGON study. J Gastroenterol. 2014;49(1):138–47.CrossRefPubMed Hayashi N, Seto C, Kato M, Komada Y, Goto S. Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1-infected patients in Japan: the DRAGON study. J Gastroenterol. 2014;49(1):138–47.CrossRefPubMed
10.
Zurück zum Zitat Fried MW, Buti M, Dore GJ, Flisiak R, Ferenci P, Jacobson I, et al. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study. Hepatology. 2013;58(6):1918–29.CrossRefPubMedPubMedCentral Fried MW, Buti M, Dore GJ, Flisiak R, Ferenci P, Jacobson I, et al. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study. Hepatology. 2013;58(6):1918–29.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Chamorro-de-Vega E, Rodriguez-Gonzalez CG, Gimenez-Manzorro A, de Lorenzo-Pinto A, Iglesias-Peinado I, Herranz A, et al. Improving pharmacotherapy outcomes in patients with hepatitis C virus infection treated with direct-acting antivirals: the GRUviC project. Int J Clin Pract. 2017;71(8):1–10.CrossRef Chamorro-de-Vega E, Rodriguez-Gonzalez CG, Gimenez-Manzorro A, de Lorenzo-Pinto A, Iglesias-Peinado I, Herranz A, et al. Improving pharmacotherapy outcomes in patients with hepatitis C virus infection treated with direct-acting antivirals: the GRUviC project. Int J Clin Pract. 2017;71(8):1–10.CrossRef
12.
Zurück zum Zitat Neukam K, Morano-Amado LE, Rivero-Juárez A, Mancebo M, Granados R, Téllez F, et al. HIV-coinfected patients respond worse to direct-acting antiviral-based therapy against chronic hepatitis C in real life than HCV-monoinfected individuals: a prospective cohort study. HIV Clin Trials. 2017;18(3):126–34.CrossRefPubMed Neukam K, Morano-Amado LE, Rivero-Juárez A, Mancebo M, Granados R, Téllez F, et al. HIV-coinfected patients respond worse to direct-acting antiviral-based therapy against chronic hepatitis C in real life than HCV-monoinfected individuals: a prospective cohort study. HIV Clin Trials. 2017;18(3):126–34.CrossRefPubMed
13.
Zurück zum Zitat Uriarte-Pinto M, Navarro-Aznarez H, De La Llama-Celis N, Arazo-Garcés P, Martínez-Sapiña AM, Abad-Sazatornil MR. Effectiveness and security of chronic hepatitis C treatment in coinfected patients in real-world. Int J Clin Pharm. 2018;40(3):608–16.CrossRefPubMed Uriarte-Pinto M, Navarro-Aznarez H, De La Llama-Celis N, Arazo-Garcés P, Martínez-Sapiña AM, Abad-Sazatornil MR. Effectiveness and security of chronic hepatitis C treatment in coinfected patients in real-world. Int J Clin Pharm. 2018;40(3):608–16.CrossRefPubMed
14.
Zurück zum Zitat Petersen T, Townsend K, Gordon LA, Sidharthan S, Silk R, Nelson A, et al. High adherence to all-oral directly acting antiviral HCV therapy among an inner-city patient population in a phase 2a study. Hepatol Int. 2016;10(2):310–9.CrossRefPubMed Petersen T, Townsend K, Gordon LA, Sidharthan S, Silk R, Nelson A, et al. High adherence to all-oral directly acting antiviral HCV therapy among an inner-city patient population in a phase 2a study. Hepatol Int. 2016;10(2):310–9.CrossRefPubMed
15.
Zurück zum Zitat Höner Zu Siederdissen C, Maasoumy B, Marra F, Deterding K, Port K, Manns MP, et al. Drug-drug interactions with novel all oral interferon-free antiviral agents in a large real-world cohort. Clin Infect Dis. 2016;62(5):561–7.CrossRefPubMed Höner Zu Siederdissen C, Maasoumy B, Marra F, Deterding K, Port K, Manns MP, et al. Drug-drug interactions with novel all oral interferon-free antiviral agents in a large real-world cohort. Clin Infect Dis. 2016;62(5):561–7.CrossRefPubMed
16.
20.
Zurück zum Zitat Thiagarajan P, Ryder SD. The hepatitis C revolution part 1: antiviral treatment options. Curr Opin Infect Dis. 2015;28(6):563–71.CrossRefPubMed Thiagarajan P, Ryder SD. The hepatitis C revolution part 1: antiviral treatment options. Curr Opin Infect Dis. 2015;28(6):563–71.CrossRefPubMed
21.
22.
Zurück zum Zitat Höner zu Siederdissen C, Buggisch P, Böker K, Schott E, Klinker H, Pathil A, et al. Treatment of hepatitis C genotype 1 infection in Germany: effectiveness and safety of antiviral treatment in a real-world setting. United Eur Gastroenterol J. 2018;6(2):213–24.CrossRef Höner zu Siederdissen C, Buggisch P, Böker K, Schott E, Klinker H, Pathil A, et al. Treatment of hepatitis C genotype 1 infection in Germany: effectiveness and safety of antiviral treatment in a real-world setting. United Eur Gastroenterol J. 2018;6(2):213–24.CrossRef
23.
Zurück zum Zitat Yang HJ, Ryoo JY, Yoo BK. Meta-analysis of the efficacy and safety of sofosbuvir for the treatment of hepatitis C virus infection. Int J Clin Pharm. 2015;37(5):698–708.CrossRefPubMed Yang HJ, Ryoo JY, Yoo BK. Meta-analysis of the efficacy and safety of sofosbuvir for the treatment of hepatitis C virus infection. Int J Clin Pharm. 2015;37(5):698–708.CrossRefPubMed
Metadaten
Titel
Implementation of a pharmaceutical care program for patients with hepatitis C treated with new direct-action antivirals
verfasst von
María Ángeles Campos Fernández de Sevilla
Marta Gallego Úbeda
Miriam Heredia Benito
Emilio García-Cabrera
Beatriz Monje García
María Tovar Pozo
Laura Delgado Téllez de Cepeda
Irene Iglesias-Peinado
Publikationsdatum
27.04.2019
Verlag
Springer International Publishing
Erschienen in
International Journal of Clinical Pharmacy / Ausgabe 2/2019
Print ISSN: 2210-7703
Elektronische ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-019-00809-3

Weitere Artikel der Ausgabe 2/2019

International Journal of Clinical Pharmacy 2/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.